References
- Kay J. E., Moore A. L., Doe S. E. A., Benzie C. R., Schonbrunner R., Schmid F. X. and Halestrap A. P. (1990) The mechanism of action of FK506. Transplant Proc, 22, 96.
- Kino T., Hatanaka H., Miyata S., Inamura N., Nishiyama M., Yajima T., Goto T., Okuhara M., Kohsaka M., Aoki H. and Ochia T. (1987) FK506, a novel immunosupressant isolated from a Streptomyces. II. Immunosupressive effect of FK506 in vitro. J Antibiot 40, 1256.
- Tocci M. J., Matkovich T. A., Collier K. A., Kvok P. et al.: (1989) Immunosupressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 43, 718–26.
- Kwaan H. C. (1987) Miscellaneous secondary thrombotic microangiopathy. Sem Hematol 24/3, 141–47.
- Mach-Pascual S., Samii K. and Beris P. (1996) Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. Am J Hematol 52, 310–312.
- Ichihashi T., Naoe T., Yoshida H., Kiyoi H., Fukutani H., Kubo K., Yamauchi T., Saito H. and Ohno R. (1992) Haemolytic-uraemic syndrome during FK506 therapy. Lancet 340, 60–61.
- Holman M. J., Gonwa T. A., Cooper B., Husberg B. S., Goldstein R. M., Gibbs J. F. and Klintmalm G. B. (1993) FK-506 associated thrombotic thrombocytopenic purpura. Transplantation 55, 205.
- Fay J. W., (1996) FK506 for the prevention of GVHD after histocompatible sibling allogeneic BMT. Blood 87, 3514–19.
- Schmidt R. J., Venkat K. K. and Dumier F. (1991) Hemolytic-uremic syndrome in a renal transplant recipient on FK506 immunosupression. Transpl Proc 23/6, 3156–57.
- McCauley J., Bronsther O., Fung J., Todo S. and Starzl T. E. (1989) Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet 30, 1516.